FDA Updates Biological Product Deviation Codes For Cber Reporting

Accurate deviation code assignment is now a sharper compliance checkpoint for QA directors and regulatory affairs leads managing Biological Product Deviation (BPD) reports submitted to FDA's Center for Biologics Evaluation and Research. FDA has refreshed its published deviation code list, reinforcing the expectation that each reportable event carries a specific, correctly matched code at the time of submission.

The code set applies to biological product manufacturers and HCT/P establishments operating under 21 CFR Parts 600 and 1271 respectively. Facilities are directed to use the deviation codes in conjunction with FDA's guidance document, Biological Product Deviation Reporting for Blood and Plasma Establishments, to determine both reportability thresholds and appropriate code selection. Misalignment between the event description and the assigned code is a documented trigger for follow-up queries and, in repeat patterns, inspection scrutiny.

For QA leads, the operational read centers on internal triage workflows: the code selected at submission locks the event into a regulatory category that shapes how CBER reviewers assess trending data across the industry. A miscoded deviation does not simply affect one report, it can distort a facility's deviation profile over time and complicate CAPA documentation during a pre-approval inspection (PAI) or routine surveillance visit.

HCT/P establishments carry a parallel obligation. Deviation reporting under 21 CFR Part 1271.350 follows a separate but structurally similar coding framework, and the updated code list addresses both biological product and HCT/P categories within a single reference. Regulatory affairs teams supporting both product types should confirm that SOPs reference the current code set and that training records reflect any code additions or reclassifications introduced in this update.

The next internal audit cycle is a practical checkpoint to validate that deviation classification procedures align with the current FDA code list before the next scheduled CBER interaction.

Source: FDA Center for Biologics Evaluation and Research via What's New Vaccines Blood Biologics RSS Feed, 30 September 2026.